PHARMANEST EXECUTIVES:
Philippe Nore, MBA
Chief Business Officer
PHARNANEST BOARD OF DIRECTORS
Mathieu M. Petitjean, Ph.D.
Chairman and CEO
CLINICAL AND MEDICAL ADVISORY BOARD
Dr. Cynthia Behling, MD
Gastrointestinal, Hepatobiliary Pathologist
U.C. San Diego, Sharp Memorial Hospital
To be Announced
NEWS AND UPDATES (2025)
Check our news archive here
September 11, 2025: PharmaNest, NIH and VCU Launch Confirmatory Retrospective Outcome Study With 1,765 Patients to Advance AI-Driven Digital Pathology in MASLD, Press release here
May 7-10, 2025: PharmaNest to present five digital Pathology and abstracts at the 2025 EASL Congress in Amsterdam, EU in collaboration with major Academic center and pharmaceutical companies developing a cure for MASH, Alcoholic Liver Disease and Cirrhosis. Press Release Here.
May 3-6, 2025: PharmaNest attends the 2025 Digestive Disease Week (DDW) in San Diego, USA to develop strategic relationships with pharmaceutical companies exploring anti-fibrotic claims in Crohn’s Disease.
May 1, 2025: PharmaNest Launches FibroMAP, the First Single-Fiber Phenotypic Tool for the Study of Fibrosis Across Biological Models and Indications. Press Release Here.
January 12-14, 2025: PharmaNest attends the 2025 JP Morgan Healthcare Conference to develop strategic relationships in the Drug Development and Investors communities.
January, 11 2025: PharmaNest to present at the 2025 MASH-Tag Conference (Deer Park, UT, USA): Along side with Dr. Andy Beck (PathAI), Dr. Dean Tai (Histoindex), Prs. Mary Rinella, Vlad Ratziu and Naim Alkhouri, Dr. Mathieu Petitjean presents PharmaNest’s contributions to “Recent Progress in Measuring Antifibrotic Effects: Data from MASH Clinical Trials” (Presentation here)
Offices:
100 Overlook Center, FL2, Princeton, NJ 08540
FibroNest Operations:
We deliver FibroNest worldwide via the Cloud.
Privacy:
Code of conduct
PharmaNest proudly participates to the E-Verify program and respects related Immigration Laws.